血浆和非小细胞肺癌恶性胸腔积液中的可溶性CD40：一种潜在的预后标志物。
Soluble CD40 in plasma and malignant pleural effusion with non-small cell lung cancer: A potential marker of prognosis.
作者信息
Mu Chuan-Yong, Qin Pang-Xue, Qu Qiu-Xia, Chen Cheng, Huang Jian-An
机构信息
Respiratory Department, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, China.
Gastrointestinal Department, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, China.
出版信息
Chronic Dis Transl Med. 2015 Mar 23;1(1):36-41. doi: 10.1016/j.cdtm.2015.02.010. eCollection 2015 Mar.
OBJECTIVE
Soluble CD40 (sCD40) is a potential modulator for both antitumor responses and CD40-based immunotherapy; however the levels and significance of sCD40 in non-small cell lung cancer (NSCLC) patients with malignant pleural effusion are unknown.
METHODS
Forty-eight patients with lung cancer were treated in our institutions from January 2008 to January 2010. Peripheral blood and pleural effusion samples were collected from each subject. sCD40 levels in plasma and malignant pleural effusions supernatant were measured. The CD40L expression on CD3t T-cells was confirmed by flow cytometric direct immunofluorescence analysis. All patients were followed up after the study ended on January 1, 2010.
RESULTS
Patients with malignant pleural effusion of NSCLC had elevated circulating and pleural effusion levels of sCD40, and these elevated sCD40 levels were associated with advanced diseases and a poor prognosis.
CONCLUSIONS
These findings indicate that elevated sCD40 may have a role in modulating antitumor responses and may also be a useful prognostic marker.
目的
可溶性CD40（sCD40）是抗肿瘤反应和基于CD40的免疫治疗的潜在调节因子；然而，sCD40在伴有恶性胸腔积液的非小细胞肺癌（NSCLC）患者中的水平及意义尚不清楚。
方法
2008年1月至2010年1月期间，我们机构对48例肺癌患者进行了治疗。采集了每位受试者的外周血和胸腔积液样本。检测血浆和恶性胸腔积液上清液中的sCD40水平。通过流式细胞术直接免疫荧光分析确认CD3⁺ T细胞上CD40L的表达。在2010年1月1日研究结束后，对所有患者进行了随访。
结果
NSCLC伴有恶性胸腔积液的患者循环血和胸腔积液中的sCD40水平升高，而这些升高的sCD40水平与疾病进展和预后不良相关。
结论
这些发现表明，升高的sCD40可能在调节抗肿瘤反应中起作用，也可能是一个有用的预后标志物。
Zotero 插件